Research & Development

The two companies intend for this partnership to ‘empower customers with bioanalytical solutions to advance drug candidates from early R&D phases through to lot release’, according to the companies’ press release.

It is planned that Allumiqs will provide biological insights and therapeutic characterisation in the early stages of a customer’s R&D work, before Prolytix will take over and offer targeted method development for stability, potency and GMP release testing. These interconnected solutions and processes are the main aim of the collaboration.

Kent MacLean, chief executive officer of Allumiqs, commented: “We found many synergies in working with the team at Prolytix in collaborative customer projects, most importantly our shared commitment to customer success. Now in partnership with Prolytix we can take all of our customers further in the drug development process with connected solutions from early R&D to lot release. Our goal is to make it simple for our customers to engage with the innovation partners they need at every stage of the drug discovery process, and our partnership with Prolytix does that.”

David Halverson, president and CEO, Prolytix, added: “This is exciting news for our customers. Our partnership with Allumiqs is a natural one that further enhances our existing portfolio of products and analytical services to support the research, development and commercialisation of IVDs, clinical diagnostics and large molecule biotherapeutics. We’ve already proven that linking our expertise and solutions together in customer engagements enables a robust scientific platform to optimise and advance biopharma research, and we look forward to building on this.”